The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Vol.
36
No.
1
January 25, 2013Jan 25, 2013
Free
DOWNLOAD THE PDF

Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer

Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas

Nexavar Improves PFS In Phase III Trial

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

Ibrutinib Produces 68% Overall Response Rate in Phase II Trial

Researchers Uncover Tumors Sensitive to Chemotherapy

Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment

Existing HER2 Drugs May Help More In Breast Cancer Treatment

Smoking Intensity and Markers Predict Cancer Aggressiveness

Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk

No Difference in Toxicity Between IMRT and PRT In Medicare Patients

NCI CTEP Approved Trials For the Month of January

FDA Expands Gleevec Indication For Children with Ph+ ALL

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account